We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

22 hedge funds and large institutions have $339M invested in China Biologic Products Holdings, Inc. in 2013 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

5% more funds holding

Funds holding: 2122 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

2% less capital invested

Capital invested by funds: $345M → $339M (-$6.11M)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.64%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
4
Increased
5
Reduced
6
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
WP
1
Warburg Pincus
New York
$317M
HSBC Holdings
2
HSBC Holdings
United Kingdom
$4.33M
Renaissance Technologies
3
Renaissance Technologies
New York
$3.42M +$693K +23,900 +25%
Invesco
4
Invesco
Georgia
$2.9M -$137K -4,736 -5%
LBA
5
Letko, Brosseau & Associates
Quebec, Canada
$2.8M +$1.86M +64,000 +195%
BIT
6
BlackRock Institutional Trust
California
$2.51M -$134K -4,636 -5%
VAM
7
Visium Asset Management
New York
$1.15M
California Public Employees Retirement System
8
California Public Employees Retirement System
California
$939K
Morgan Stanley
9
Morgan Stanley
New York
$892K +$641K +22,096 +250%
ACM
10
Ativo Capital Management
Illinois
$780K +$124K +4,294 +19%
SIM
11
Spark Investment Management
New York
$613K +$165K +5,700 +37%
GCP
12
GSA Capital Partners
United Kingdom
$499K -$307K -10,600 -38%
New York State Common Retirement Fund
13
New York State Common Retirement Fund
New York
$462K
WC
14
Wexford Capital
Florida
$349K +$351K +12,100 New
Two Sigma Investments
15
Two Sigma Investments
New York
$237K +$239K +8,245 New
RA
16
Royce & Associates
New York
$84K
U
17
UBS
Switzerland
$39K +$39.3K +1,355 New
TRCT
18
Tower Research Capital (TRC)
New York
$36K -$899 -31 -2%
BA
19
BlackRock Advisors
Delaware
$10K -$38.9K -1,342 -80%
OA
20
OFI Advisors
Pennsylvania
$6K -$232 -8 -4%
Bank of America
21
Bank of America
North Carolina
$3K
Citigroup
22
Citigroup
New York
$2K +$2.23K +77 New
T. Rowe Price Associates
23
T. Rowe Price Associates
Maryland
-$5.16M -176,729 Closed
BG
24
BlackRock Group
United Kingdom
-$211K -7,230 Closed
BJ
25
BlackRock Japan
Japan
-$29K -992 Closed

CBPO Hedge Fund Activity: Q4 2013 in Review

22 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q4 2013, worth a combined $339M — down 1.8% from $345M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CBPO positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 6 trimmed.

The largest buyer was Letko, Brosseau & Associates, adding an estimated $1.86M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $5.16M sold.

  • 22 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q4 2013, up from 21 in Q3 2013.
  • Funds reported $339M of China Biologic Products Holdings, Inc. stock for Q4 2013, down 1.8% quarter-over-quarter.
  • 4 funds opened new China Biologic Products Holdings, Inc. positions in Q4 2013 and 3 closed out, a net change of +1 holder.
  • The largest China Biologic Products Holdings, Inc. buyer in Q4 2013 was Letko, Brosseau & Associates, an estimated $1.86M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q4 2013 was T. Rowe Price Associates, an estimated $5.16M sold.

Based on aggregated 13F filings for Q4 2013.